Wardman M, Chintakayala P, Heywood C. The valuation and demand impacts of the worthwhile use of travel time with specific reference to the digital revolution and endogeneity. Transportation. 2019 Oct 23;47:1515-40. doi: 10.1007/s11116-019-10059-x
Batley R, Bates J, Bliemer M, Borjesson M, Bourdon J, Cabral MO, Chintakayala P, Choudhury C, Daly A, Dekker T, Drivyla E, Fowkes T, Hess S, Heywood C, Johnson D, Laird J, Mackie P, Parkin J, Sanders S, Sheldon R, Wardman M, Worsley T. New appraisal values of travel time saving and reliability in Great Britain. Transportation. 2019 Jun;46:583-621. doi: 10.1007/s11116-017-9798-7
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Bristow AL, Wardman M, Chintakayala VPK. International meta-analysis of stated preference studies of transportation noise nuisance. Transportation. 2015;42:71-100. doi: 10.1007/s11116-014-9527-4
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.